NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
(TSX-V:NRX),(Frankfurt:J90),(Boerse Stuttgart – Freiverkehr:J90),(Boerse Muenchen – Freiverkehr:J90),(OTC US:NRXBF),(Other OTC:NRXBF), TORONTO and HAIFA, Israel, Jan. 21, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (“NurExone” or the “Company“), a developer of exosome-based therapies for regenerative medicine, is pleased to announce that, subject to TSX Venture Exchange (“TSXV“) approval, it has closed […]